• ALDH2 Activation Promotes Cardiomyocyte Proliferation in Hea

  2026-07-23

  The referenced study demonstrates that ALDH2 activation, including through Alda 1, significantly extends the proliferative window of cardiomyocytes in mice and delays heart failure progression induced by pressure overload. These findings offer a mechanistic advance for cardiac regeneration research, with implications for developing innovative strategies in cardioprotection.

• (-)-JQ1 as a Precision Control: Redefining BET Inhibitor Ass

  2026-07-23

  Explore the unique role of (-)-JQ1 as a JQ1 stereoisomer and rigorous negative control in BET bromodomain research. This article uncovers how advanced use of (-)-JQ1 transforms assay interpretation, leveraging new mechanistic insights for epigenetics research and cancer biology.

• Cy3 Goat Anti-Rabbit IgG (H+L) Antibody for Fluorescence Wor

  2026-07-22

  The Cy3 Goat Anti-Rabbit IgG (H+L) Antibody enables sensitive and specific detection of rabbit primary antibodies in immunofluorescence, immunohistochemistry, and related immunoassays. It is not suitable for diagnostic or therapeutic use, and care should be taken to adhere closely to storage and handling guidelines to maintain fluorescence stability.

• LL-37 Peptides Disrupt Biofilms in Multidrug-Resistant A. ba

  2026-07-22

  The reference study demonstrates that the human antimicrobial peptide LL-37 and its fragments possess both potent bactericidal and antibiofilm activities against multidrug-resistant Acinetobacter baumannii. These findings highlight the therapeutic potential of cathelicidin-derived peptides as alternatives for combating intractable nosocomial infections.

• ALDH2 Activation Promotes Cardiomyocyte Proliferation in Hea

  2026-07-21

  This study demonstrates that pharmacological activation of ALDH2, specifically using Alda 1, prolongs the proliferative window of cardiomyocytes and delays heart failure progression in a mouse model of pressure overload. The findings offer a new experimental avenue for cardiac regeneration research by targeting aldehyde detoxification and cell cycle regulation in postnatal and adult hearts.

• CUDC-907: Technical Guidance for Dual PI3K and HDAC Inhibiti

  2026-07-21

  CUDC-907 is a dual PI3K and HDAC inhibitor designed for in vitro research requiring precise and concurrent modulation of PI3K/AKT and HDAC pathways, especially in cancer cell models. It is not suitable for diagnostic, therapeutic, or clinical applications and should be handled following strict laboratory protocols.

• JAK Inhibitors and Endothelial Dysfunction: Insights from Co

  2026-07-20

  This article analyzes new evidence detailing how different JAK inhibitors, including tofacitinib citrate, affect endothelial inflammation, adhesion molecule expression, and apoptosis under conditions modeling inflammatory cardiovascular risk. The findings clarify similarities and distinctions among JAK inhibitors, offering researchers a nuanced framework for understanding their roles in immune regulation and vascular biology.

• Cisapride (R 51619): Precision Tool for Cardiac Electrophysi

  2026-07-20

  Cisapride (R 51619) powers predictive cardiac electrophysiology and arrhythmia research with dual 5-HT4 receptor agonism and hERG channel inhibition. Leveraging high-content imaging and iPSC-derived cardiomyocytes, researchers can rapidly profile drug-induced cardiotoxicity and streamline early-stage safety assessment workflows.

• Syringin in RCC: Mechanistic Insights and Translational Impa

  2026-07-19

  This thought-leadership article explores the scientific and translational landscape of Syringin, a potent natural product, as a novel modulator of the EGFR/PI3K/Akt pathway in renal cell carcinoma (RCC). Drawing on the latest experimental evidence, we examine the mechanistic underpinnings, protocol recommendations, and future directions for researchers aiming to overcome sunitinib resistance. The discussion is grounded in evidence, highlights APExBIO’s Syringin as a research-grade standard, and connects advanced workflows to actionable translational oncology strategies.

• GPR107 Deficiency Drives Collagen IV Accumulation in Diabeti

  2026-07-18

  Xu et al. reveal that GPR107 deficiency in podocytes exacerbates diabetic nephropathy by disrupting collagen type IV turnover and amplifying pro-fibrotic angiotensin II signaling. These findings clarify the mechanistic link between defective receptor endocytosis and glomerular basement membrane thickening, highlighting novel therapeutic directions.

• BIBP 3226 trifluoroacetate: Precision Tool for NPY/NPFF Rese

  2026-07-17

  BIBP 3226 trifluoroacetate unlocks advanced dissection of the NPY/NPFF axis in anxiety, analgesia, and cardiovascular models. Its high specificity and robust performance in co-culture and signaling assays set a new benchmark for reproducibility and mechanistic clarity.

• LMCD1 Upregulation Drives Corneal Fibrosis via TGF-β1/SMAD3

  2026-07-17

  This study identifies LMCD1 as a novel mediator of corneal myofibroblast differentiation and fibrosis, revealing that its upregulation is induced by TGF-β1 through the SMAD3 pathway. The findings highlight LMCD1 as a promising molecular target for future therapeutic strategies against corneal fibrosis.

• Syringin Natural Product: Optimizing RCC Bioactive Workflows

  2026-07-16

  Syringin is redefining renal cell carcinoma (RCC) research by synergizing with sunitinib and selectively modulating the EGFR/PI3K/Akt pathway. This guide distills high-impact workflows and troubleshooting strategies for leveraging APExBIO's high-purity Syringin in apoptosis and bioactive compound screening assays.

• Annexin V Expression and Purification for Apoptosis Detectio

  2026-07-16

  This study describes a robust method for expressing and purifying recombinant annexin V, enabling sensitive detection of apoptotic cell membrane alterations via phosphatidylserine exposure. The protocol streamlines apoptotic cell identification in mammalian systems, supporting high-yield production and downstream applications such as flow cytometry.

• Alda 1 as a Next-Generation ALDH2 Activator for Cardioprotec

  2026-07-15

  Explore how Alda 1, a potent ALDH2 activator, sets a new benchmark for cardiac ischemia research and radiation-induced dermatitis mitigation. This article uniquely dissects the mechanistic insights and translational impact of ALDH2 activation for preclinical assay design.

16342 records 1/1090 page Next 12345 下5页 Last page